Montelukast

Generic Name: Montelukast

Brand Names: Singulair

Drug Type: Small Molecule

Chemical Formula: C_₃₅H_₃₆ClNO_₃S

CAS Number: 158966-92-8

Unique Ingredient Identifier: MHM278SD3E

Background: Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs. Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticos...

Indication: Montelukast is indicated for:
...

Associated Conditions: Asthma, Exercise-Induced Bronchospasm, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis

Associated Therapies: -

Clinical Trials

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 2

Not yet recruiting

Conditions: Plasma Cell Myeloma Refractory

Interventions: Drug: Isatuximab SC-OBDS
Drug: Montelukast
Drug: Dexamethasone
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Methylprednisolone
Drug: Carfilzomib

First Posted Date: 2024-04-10

Last Posted Date: 2024-11-22

Lead Sponsor: Sanofi

Target Recruit Count: 64

Registration Number: NCT06356571

Montelukast in Parkinson Disease

Phase 2

Recruiting

Conditions: Parkinson Disease

Interventions: Drug: levodopa-carbidopa
Drug: Montelukast

First Posted Date: 2023-11-02

Last Posted Date: 2024-07-18

Lead Sponsor: Mostafa Bahaa

Target Recruit Count: 60

Registration Number: NCT06113640

Locations: 🇪🇬
Faculty of Medicine, Mansoura University, Mansoura, Egypt

A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

Phase 4

Recruiting

Conditions: Fabry's Disease

Interventions: Drug: AGALSIDASE BETA (GZ419828)
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Dexamethasone
Drug: Montelukast

First Posted Date: 2023-08-31

Last Posted Date: 2024-08-09

Lead Sponsor: Sanofi

Target Recruit Count: 18

Registration Number: NCT06019728

Locations: 🇺🇸
Emory University School of Medicine Site Number : 1005, Atlanta, Georgia, United States
🇺🇸
Lysosomal and Rare Disorders Research and Treatment Center, Inc Site Number : 1002, Fairfax, Virginia, United States
🇺🇸
Infusion Associates Site Number : 1001, Grand Rapids, Michigan, United States

and more 2 locations

Clinical Evaluation of Montelukast in Veterans with Gulf War Illness

Phase 1

Not yet recruiting

Conditions: Gulf War Syndrome

Interventions: Other: Placebo
Drug: Montelukast

First Posted Date: 2023-08-15

Last Posted Date: 2024-11-06

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 80

Registration Number: NCT05992311

Locations: 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, Texas, United States

Effect of Montelukast on Doxorubicin Induced Cardiotoxicity in Breast Cancer

Not Applicable

Recruiting

Conditions: Breast Cancer
Doxorubicin Induced Cardiotoxicity

Interventions: Other: Placebo
Drug: Montelukast

First Posted Date: 2023-07-25

Last Posted Date: 2024-08-09

Lead Sponsor: Damanhour University

Target Recruit Count: 50

Registration Number: NCT05959889

Locations: 🇪🇬
Damanhour Oncology Center, Damanhūr, Elbehairah, Egypt

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Phase 2

Recruiting

Conditions: Lung Diseases
Bronchiolitis Obliterans
Chronic Graft Versus Host Disease
Bronchiolitis Obliterans Syndrome

Interventions: Drug: Belumosudil
Drug: Fluticasone
Drug: Azithromycin
Drug: Prednisone
Drug: Montelukast

First Posted Date: 2023-06-28

Last Posted Date: 2024-08-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 45

Registration Number: NCT05922761

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

Phase 2

Recruiting

Conditions: Refractory Multiple Myeloma
Relapsed Multiple Myeloma

Interventions: Drug: Iberdomide
Drug: Carfilzomib
Drug: Daratumumab
Drug: Dexamethasone
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Montelukast

First Posted Date: 2023-06-09

Last Posted Date: 2024-03-01

Lead Sponsor: Carl Ola Landgren, MD, PhD

Target Recruit Count: 30

Registration Number: NCT05896228

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)

Phase 3

Completed

Conditions: Covid19

Interventions: Other: Placebo
Drug: Montelukast

First Posted Date: 2023-06-08

Last Posted Date: 2024-08-16

Lead Sponsor: Susanna Naggie, MD

Target Recruit Count: 1453

Registration Number: NCT05894577

Locations: 🇺🇸
Tabitha B. Fortt, M.D., LLC, Stamford, Connecticut, United States
🇺🇸
Lamb Health, LLC, Gilbert, Arizona, United States
🇺🇸
Emory Healthcare, Atlanta, Georgia, United States

and more 105 locations

A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BMS-986196
Drug: Caffeine
Drug: Montelukast
Drug: Flurbiprofen
Drug: Omeprazole
Drug: Midazolam
Drug: Digoxin
Drug: Pravastatin

First Posted Date: 2023-05-10

Last Posted Date: 2023-09-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 18

Registration Number: NCT05852769

Locations: 🇺🇸
ICON plc, Millcreek, Utah, United States

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Drug: Isatuximab
Drug: Carfilzomib
Drug: Dexamethasone
Drug: Dexamethasone IV
Drug: Montelukast
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Methylprednisolone

First Posted Date: 2023-01-30

Last Posted Date: 2024-11-14

Lead Sponsor: Sanofi

Target Recruit Count: 74

Registration Number: NCT05704049

Locations: 🇦🇺
Investigational Site Number : 0360002, Wollongong, New South Wales, Australia
🇧🇷
Hospital Mae de Deus Site Number : 0760002, Porto Alegre, Rio Grande Do Sul, Brazil
🇦🇺
Investigational Site Number : 0360001, Fitzroy, Victoria, Australia

and more 14 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy